Xoma reports Xanelim Phase I/II data

XOMA said data from an open-label, 12-week Phase I/II trial showed 46 of 61 (75 percent) patients with

Read the full 184 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE